Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
株式のランク #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
株価
$0.12164306
最終同期: 2024-11-11
時価総額
$38.53M
変化(1日)
-4.14%
変化(1年)
0.00%
AU
取引 PharmAust Limited (PAA)

カテゴリー

PharmAust Limited(PAA)の収益
Jun 2024 時点の収益 TTM: $572.45K
PharmAust Limited の最新の財務報告によると、現在の収益 (TTM) は $572.45K です。2023 年には $1.88M の収益があり、これは 2022 年の $2.33M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
PharmAust Limited の収益履歴(2001 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $572.45K 0.00%
2024 0.00 -100.00%
2023 $1.88M -19.32%
2022 $2.33M 45.33%
2021 $1.60M -27.22%
2020 $2.21M -27.76%
2019 $3.05M 26.47%
2018 $2.41M -5.23%
2017 $2.55M 25.80%
2016 $2.02M 10.90%
2015 $1.83M -0.20%
2014 $1.83M 17.05%
2013 $1.56M -5.48%
2012 $1.65M -0.67%
2011 $1.66M 19.79%
2010 $1.39M -2.17%
2009 $1.42M -47.01%
2008 $2.68M -55.73%
2007 $6.05M 33.53%
2006 $4.53M 85.63%
2005 $2.44M 1,047.74%
2004 $212.83K 366.98%
2003 $45.58K -88.07%
2002 $381.98K 0.00%
2001 0.00 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 2,205,224.96%
US
$6.02B 1,051,752.00%
NL
$15.70B 2,741,683.32%
AU
$2.23B 389,106.85%
US
- -
CH